We performed a large-scale meta-analysis of 40 papers and 2,805 NSCLC patients, reviewing controversial evidence for the diagnostic role of cfDNA testing for the detection of KRAS mutations in NSCLC. Here, KRAS is linked to non-small cell lung carcinoma.